LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Propylenglykol Evolan

(propylene glycol)

5.4.1-2020-42323
2020-0477

This module reflects the scientific discussion for the approval of Propylenglykol Evolan. The procedure was finalised on 2021-04-26. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

I. INTRODUCTION

The application for Propylenglykol Evolan, 200mg/g, cream, is submitted according to Article 10(3) of Directive 2001/83/EC. The applicant, Evolan Pharma AB applies for a marketing authorisation in Sweden through a National Procedure.

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Propyderm, 20%, cream, authorized in SE since 2001, with ACO Hud Nordic AB as marketing authorization holder.

For approved indications, see the Summary of Product Characteristics.

For recommendations to the marketing authorisation not falling under Article 21a/22 of Directive 2001/83/EC and conditions to the marketing authorisation pursuant to Article 21a or 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

Pharmacodynamic, pharmacokinetic and toxicological properties of propylene glycol are well known. As propylene glycol is a widely used, well-known active substance, no further studies are required, and the applicant provides none. Overview based on literature review is, thus, appropriate.

The non-clinical overview on the pre-clinical pharmacology, pharmacokinetics and toxicology is adequate and is considered sufficient to support the application.

Environmental Risk Assessment (ERA)
A justification for not performing an ERA has been submitted. Propylene glycol is a high tonnage chemical used in a variety of processes and consumer products. Based on the common presence in the environment, the product is unlikely to alter the concentration or distribution of propylene glycol in the environment.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

Bioequivalence studies are not possible to perform and are not considered needed for a moisturizing cream. Absorption of propylene glycol through intact skin is negligible but may be increased in case of skin abrasion. No interactions with other medicinal products are expected. There are no data in the literature suggesting that data on propylene glycol in the treatment of dry skin are limited to certain sub-groups of the populations, due to any intrinsic or extrinsic factor.

IV.2 Pharmacodynamics

Propylene glycol is considered a well-known constituent of moisturizing creams. The mode of action of propylene glycol in Propylenglykol Evolan cream is the same as in the reference product Propyderm® cream. The water-binding ability and antimicrobial ability of propylene glycol contribute to normalization of dry skin. The cream base composition delivers propylene glycol into the skin and enhances its therapeutic efficacy i.e. the moisturizing, anti-pruritic and protective effects.

IV.3 Clinical efficacy

The efficacy of propylene glycol in the treatment of dry skin of different origin is considered well known. The applicant has reviewed the use of propylene glycol in dry skin and in eczema such as atopic dermatitis with emphasis on its antimicrobial properties. Furthermore, a clinical study in patients with dry skin is described when treatment with Propyless® was compared with Fenuril® (containing urea 4% and sodium chloride 4%).

Since the pharmaceutical composition of Propylenglykol Evolan cream is assessed as similar to Propyderm® cream, the clinical efficacy will be approximately the same for the two medicinal products.

IV.4 Clinical safety

The safety profile of propylene glycol in the treatment of dry skin of different origin is considered well known.

Since the pharmaceutical composition of Propylenglykol Evolan cream is assessed as similar to Propyderm® cream, the clinical safety will be approximately the same for the two medicinal products.

IV.5 Risk Management Plan

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Propylenglykol Evolan.

Routine pharmacovigilance is suggested, and no additional pharmacovigilance activities are proposed by the applicant, which is endorsed.

Summary of the RMP
The submitted Risk Management Plan, version 0.1 signed 30 December 2019 is considered acceptable.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the MPA;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time, but via different procedures.

V. USER CONSULTATION

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to Canoderm 5% cream SE/H/0556/001/MR concerning content and Natriumklorid Evolan 500 mg capsules, 5.4.1-2014-103368 concerning layout. The bridging report submitted by the applicant has been found acceptable.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

This application concerns a generic version of propylene glycol, formulated as a moisturizing cream. The therapeutic indication is treatment of dry skin.

The quality of the generic product Propylenglykol Evolan is found adequate. There are no objections to approval of Propylenglykol Evolan from a non-clinical point of view.

The efficacy and safety of propylene glycol in the treatment of dry skin of different origin is considered well known. No formal clinical efficacy and safety study with Propylenglykol Evolan cream has been performed. The product can be approved from a clinical perspective based on pharmaceutical similarity to Propyderm® cream. A similar clinical efficacy and safety profile of Propylenglykol Evolan cream and Propyderm® cream is anticipated.

The product information is acceptable. The benefit/risk ratio is considered positive and the application for Propylenglykol Evolan, 200mg/g, cream, is therefore recommended for approval provided that the applicant commits to perform a number of post approval commitments to be reported back to the MPA within predefined timeframes. A preliminary list of such commitments is specified below.

List of recommendations not falling under Article 21a/22 of Directive 2001/83/EC in case of a positive benefit risk assessment

Description	Due date
Quality: The specification for the finished product at release and shelf-life has been updated with a test for viscosity. It is agreed that limits could be set after finishing the stability studies.	Q1 2022

List of conditions pursuant to Article 21a or 22 of Directive 2001/83/EC

N/A

VII. APPROVAL

Propylenglykol Evolan, 200mg/g, cream was approved in the national procedure on 2021-04-26.

LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected (Yes/No)	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se